|
Basic Scientific Strategies |
|
|
iUse of Peptide antibiotics/antimicrobial peptides(AMPs) |
Target cell membrane directly or an intracellular target. Can also trigger immune response to combat diseases. |
Pasupuleti et al., 2012, Egorov et al., 2018
|
|
iiUse of Carbohydrate modified compounds |
Target cell wall, biosynthetic pathway of peptidoglycan layer, small or large subunit of ribosome etc. |
Ramirez et al., 2010, Jeong et al., 2017
|
|
iiiUse of Non-antibacterials |
Enhance activity of conventional antibiotics |
Pires et al., 2017 |
|
ivUse of Combinations of antibiotics andcompounds |
Combinations of antibiotics are directed towards multiple targets |
Silver et al., 2007, Deshayes et al., 2017
|
|
II |
Advanced Molecular Strategies |
|
|
iPhenotypic conversion of drug-resistant todrug-sensitive bacteria |
Specific sequence insertion in plasmid DNA to produce specific proteins leading to conversion of drug-resistant to drug-sensitive bacteria |
Guerrier et al., 1997, Toney et al., 1998, Alfonso et al., 2007, Jackson et al., 2016
|
|
iiApplication of DNA and mRNA vaccines |
Specific sequence insertion in plasmid DNA or directly in mRNA to produce a humoral immune response |
Pizza et al., 2000, Endmann et al., 2014, Jansen et al., 2018, Zhang et al., 2019
|
|
iiiBacteriophage therapy |
Bacteriophages attach themselves on specific bacterial cells which result in lysing/killing of the host pathogenic bacteria, or phages insert their DNA into the bacterial genome and it gets replicated along with the host DNA machinery |
Alisky et al., 1998, Malik et al., 2019, Malik et al., 2020
|
|
ivGene editing technology |
Insertion, deletion or point mutation of specific genes |
Schouten et al., 2006, Holme et al., 2012, Waltz, 2015, Kumar et al., 2020
|
|
vCRISPR/Cas gene editing system |
Gene silencing or gene editing is done to inactivate gene causing resistance |
Pak, 2014, Rodrigues et al., 2019
|